B. Braun Medical Patent-Cliff Exposure & CMS Drug Spending Portfolio

B. Braun Medical (Irvine, CA): 3 reconciled FDA prescription therapies, $16.1M 2024 CMS Part D & Medicaid spend, and 41 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterIrvine, CA
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$16.1M
2024 Medicare Part D Spend$48K
2024 Medicaid Spend$16.1M
California HCAI SB 17 Filings41 WAC filings (max 217.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for B. Braun Medical across sibling Meru public-data platforms.